Adrenomedullin function in vascular endothelial cells: Insights from genetic mouse models

Current Hypertension Reviews

Volumn 7, Issue 4, 2011, Pages 228-239

  Karpinich, Natalie O ^a   Hoopes, Samantha L ^a   Kechele, Daniel O ^a   Lenhart, Patricia M ^a   Caron, Kathleen M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenomedullin; Angiogenesis; CLR; Endothelial; Lymphangiogenesis; Mouse model; Permeability; RAMPs

Indexed keywords

ADRENOMEDULLIN; CALCITONIN RECEPTOR LIKE RECEPTOR; G PROTEIN COUPLED RECEPTOR; PROADRENOMEDULLIN; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; RECEPTOR ACTIVITY MODIFYING PROTEIN 3;

CARDIOVASCULAR DISEASE; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; EMBRYO DEVELOPMENT; GENE TARGETING; GENETIC MODEL; INJURY; MEDICAL LITERATURE; NONHUMAN; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; WOUND HEALING;

EID: 84857132305     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/157340211799304761     Document Type: Review

References (192)

1. Gibbons C, Dackor R, Dunworth W, Fritz-Six K, Caron KM. Receptor Activity-Modifying Proteins: RAMPing up Adrenomedullin Signaling. Mol Endocrinol 2007; 21(4): 783-96.
2. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005; 51(10): 1823-9.
3. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009; 302(1): 49-57.
4. Khan SQ, O'Brien RJ, Struck J, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007; 49(14): 1525-32.
5. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005; 9(6): R816-24.
6. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Proadrenomedullin to predict severity and outcome in community- acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10(3): R96.
7. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393(6683): 333-9.
8. Nagaya N, Mori H, Murakami S, Kangawa K, Kitamura S. Adrenomedullin: angiogenesis and gene therapy. Am J Physiol Regul Integr Comp Physiol. 2005; 288(6): R1432-7.
9. Ishimitsu T, Ono H, Minami J, Matsuoka H. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 2006; 111(3): 909-27.
10. Julian M, Cacho M, Garcia MA, et al. Adrenomedullin: a new target for the design of small molecule modulators with promising pharmacological activities. Eur J Med Chem 2005; 40(8): 737-50.
11. Jin D, Harada K, Ohnishi S, Yamahara K, Kangawa K, Nagaya N. Adrenomedullin induces lymphangiogenesis and ameliorates secondary lymphoedema. Cardiovasc Res 2008; 80(3): 339-45.
12. Miyashita K, Itoh H, Sawada N, et al. Adrenomedullin provokes endothelial Akt activation and promotes vascular regeneration both in vitro and in vivo. FEBS Lett 2003; 544(1-3): 86-92.
13. Kim W, Moon SO, Sung MJ, et al. Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. FASEB J 2003; 17(13): 1937-9.
14. Fernandez-Sauze S, Delfino C, Mabrouk K, et al. Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 2004; 108(6): 797-804.
15. Kato H, Shichiri M, Marumo F, Hirata Y. Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial cells. Endocrinology 1997; 138(6): 2615-20.
16. Zhou M, Simms HH, Wang P. Adrenomedullin and adrenomedullin binding protein-1 attenuate vascular endothelial cell apoptosis in sepsis. Ann Surg 2004; 240(2): 321-30.
17. Miyashita K, Itoh H, Sawada N, et al. Adrenomedullin promotes proliferation and migration of cultured endothelial cells. Hypertens Res 2003; 26 Suppl: S93-8.
18. Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A, et al. The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J Clin Invest 2008; 118(1): 29-39.
19. Hippenstiel S, Witzenrath M, Schmeck B, et al. Adrenomedullin reduces endothelial hyperpermeability. Circ Res 2002; 91(7): 618-25.
20. Kis B, Deli MA, Kobayashi H, et al. Adrenomedullin regulates blood-brain barrier functions in vitro. Neuroreport 2001; 12(18): 4139-42.
21. Muller HC, Witzenrath M, Tschernig T, et al. Adrenomedullin attenuates ventilator-induced lung injury in mice. Thorax 2010; 65(12): 1077-84.
22. Fritz-Six KL, Dunworth WP, Li M, Caron KM. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest 2008; 118(1): 40-50.
23. Petrova TV, Makinen T, Makela TP, et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. Embo J 2002; 21(17): 4593-9.
24. Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 2003; 162(2): 575-86.
25. Dunworth WP, Fritz-Six KL, Caron KM. Adrenomedullin stabilizes the lymphatic endothelial barrier in vitro and in vivo. Peptides 2008; 29(12): 2243-9.
26. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001; 22(7): 368-76.
27. Lowes VL, Ip NY, Wong YH. Integration of signals from receptor tyrosine kinases and g protein-coupled receptors. Neurosignals 2002; 11(1): 5-19.
28. Yurugi-Kobayashi T, Itoh H, Schroeder T, et al. Adrenomedullin/ cyclic AMP pathway induces Notch activation and differentiation of arterial endothelial cells from vascular progenitors. Arterioscler Thromb Vasc Biol 2006; 26(9): 1977-84.
29. Guidolin D, Albertin G, Spinazzi R, et al. Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: Involvement of the vascular endothelial growth factor receptor 2. Peptides 2008; 29(11): 2013-23.
30. Caron KM, Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional Adrenomedullin gene. Proc Natl Acad Sci USA 2001; 98(2): 615-9.
31. Shindo T, Kurihara Y, Nishimatsu H, et al. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001; 104(16): 1964-71.
32. Shimosawa T, Shibagaki Y, Ishibashi K, et al. Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation 2002; 105(1): 106-11.
33. Dackor RT, Fritz-Six K, Dunworth WP, Gibbons CL, Smithies O, Caron KM. Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. Mol Cell Biol 2006; 26(7): 2511-8.
34. Dackor R, Fritz-Six K, Smithies O, Caron K. Receptor activitymodifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age. J Biol Chem. 2007; 282(25): 18094-9.
35. Czyzyk TA, Ning Y, Hsu MS, et al. Deletion of peptide amidation enzymatic activity leads to edema and embryonic lethality in the mouse. Dev Biol. 2005; 287(2): 301-13.
36. Yang JT, Rayburn H, Hynes RO. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development 1995; 121(2): 549-60.
37. Riley P, Anson-Cartwright L, Cross JC. The Hand1 bHLH transcription factor is essential for placentation and cardiac morphogenesis. Nat Genet 1998; 18(3): 271-5.
38. Jaber M, Koch WJ, Rockman H, et al. Essential role of betaadrenergic receptor kinase 1 in cardiac development and function. Proc Natl Acad Sci USA 1996; 93(23): 12974-9.
39. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. Embo J 1995; 14(23): 5884-91.
40. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87(7): 1171-80.
41. Kim K, Drummond I, Ibraghimov-Beskrovnaya O, Klinger K, Arnaout MA. Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 2000; 97(4): 1731-6.
42. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98(6): 769-78.
43. ] Francois M, Caprini A, Hosking B, et al. Sox18 induces development of the lymphatic vasculature in mice. Nature. 2008; 456(7222): 643-7.
44. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004; 5(1): 74-80.
45. Wigle JT, Harvey N, Detmar M, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. Embo J 2002; 21(7): 1505-13.
46. Hong YK, Detmar M. Prox1, master regulator of the lymphatic vasculature phenotype. Cell Tissue Res 2003; 314(1): 85-92.
47. [] Kahn ML. Blood is thicker than lymph. J Clin Invest 2008; 118(1): 23-6.
48. Shindo T, Kurihara H, Maemura K, et al. Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature. Circulation 2000; 101(19): 2309-16.
49. Tam CW, Husmann K, Clark NC, et al. Enhanced vascular responses to adrenomedullin in mice overexpressing receptor- activity-modifying protein 2. Circ Res 2006; 98(2): 262-70.
50. Kitamura K, Ichiki Y, Tanaka M, et al. Immunoreactive adrenomedullin in human plasma. FEBS Lett. 1994; 341(2-3): 288-90.
51. Martinez A, Hodge DL, Garayoa M, Young HA, Cuttitta F. Alternative splicing of the proadrenomedullin gene results in differential expression of gene products. J Mol Endocrinol 2001; 27(1): 31-41.
52. Nakamura M, Yoshida H, Hiramori K. Comparison of vasodilator potency of adrenomedulling and proadrenomedullin N-terminal 20 peptide in human. Life Sci 1999; 65(20): 2151-6.
53. Li J, Ren Y, Dong X, Zhong G, Wu S, Tang C. Roles of different peptide fragments derived from proadrenomedullin in the regulation of vascular tone in isolated rat aorta. Peptides 2003; 24(4): 563-8.
54. Hay DL, Smith DM. Knockouts and transgenics confirm the importance of adrenomedullin in the vasculature. Trends Pharmacol Sci 2001; 22(2): 57-9.
55. Bomberger JM, Parameswaran N, Hall CS, Aiyar N, Spielman WS. Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking. J Biol Chem 2005; 280(10): 9297-307.
56. Bomberger JM, Spielman WS, Hall CS, Weinman EJ, Parameswaran N. Receptor activity-modifying protein (RAMP) isoform-specific regulation of adrenomedullin receptor trafficking by NHERF-1. J Biol Chem 2005; 280(25): 23926-35.
57. Nicoli S, Tobia C, Gualandi L, De Sena G, Presta M. Calcitonin receptor-like receptor guides arterial differentiation in zebrafish. Blood 2008; 111(10): 4965-72.
58. Iimuro S, Shindo T, Moriyama N, et al. Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res 2004; 95(4): 415-23.
59. Yaniv K, Isogai S, Castranova D, Dye L, Hitomi J, Weinstein BM. Live imaging of lymphatic development in the zebrafish. Nat Med 2006; 12(6): 711-6.
60. Isogai S, Hitomi J, Yaniv K, Weinstein BM. Zebrafish as a new animal model to study lymphangiogenesis. Anat Sci Int 2009; 84(3): 102-11.
61. Geudens I, Herpers R, Hermans K, et al. Role of delta-like-4/Notch in the formation and wiring of the lymphatic network in zebrafish. Arterioscler Thromb Vasc Biol 2010; 30(9): 1695-702.
62. Di Iorio R, Marinoni E, Scavo D, Letizia C, Cosmi EV. Adrenomedullin in pregnancy. Lancet. 1997; 349(9048): 328.
63. Minegishi T, Nakamura M, Abe K, et al. Adrenomedullin and atrial natriuretic peptide concentrations in normal pregnancy and pre- eclampsia. Mol Hum Reprod. 1999; 5(8): 767-70.
64. Kobayashi K, Kubota T, Aso T, Hirata Y, Imai T, Marumo F. Immunoreactive adrenomedullin (AM) concentration in maternal plasma during human pregnancy and AM expression in placenta. Eur J Endocrinol 2000; 142(6): 683-7.
65. Hoshimoto K, Hayashi M, Ohkura T. Mature adrenomedullin concentrations in plasma during pregnancy. J Matern Fetal Neonatal Med 2002; 11(2): 126-9.
66. Hayashi Y, Ueyama H, Mashimo T, Kangawa K, Minamino N. Circulating mature adrenomedullin is related to blood volume in full-term pregnancy. Anesth Analg 2005; 101(6): 1816-20.
67. Senna AA, Zedan M, el-Salam GE, el-Mashad AI. Study of plasma adrenomedullin level in normal pregnancy and preclampsia. Medscape J Med. 2008; 10(2): 29.
68. Marinoni E, Casciani V, Marianetti V, Di Rocco A, Moscarini M, Di Iorio R. Localization and distribution of adrenomedullin receptor in the human placenta: changes with gestational age. J Reprod Med. 2007; 52(9): 831-8.
69. Cameron VA, Autelitano DJ, Evans JJ, et al. Adrenomedullin expression in rat uterus is correlated with plasma estradiol. Am J Physiol Endocrinol Metab 2002; 282(1): E139-46.
70. Li M, Yee D, Magnuson TR, Smithies O, Caron KM. Reduced maternal expression of adrenomedullin disrupts fertility, placentation, and fetal growth in mice. J Clin Invest 2006; 116(10): 2653-62.
71. Nikitenko LL, Brown NS, Smith DM, MacKenzie IZ, Bicknell R, Rees MC. Differential and cell-specific expression of calcitonin receptor-like receptor and receptor activity modifying proteins in the human uterus. Mol Hum Reprod 2001; 7(7): 655-64.
72. Gratton RJ, Gluszynski M, Mazzuca DM, Nygard K, Han VK. Adrenomedullin messenger ribonucleic acid expression in the placentae of normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2003; 88(12): 6048-55.
73. Marinoni E, Di Iorio R, Letizia C, Villaccio B, Scucchi L, Cosmi EV. Immunoreactive adrenomedullin in human fetoplacental tissues. Am J Obstet Gynecol 1998; 179(3 Pt 1): 784-7.
74. Montuenga LM, Martinez A, Miller MJ, Unsworth EJ, Cuttitta F. Expression of adrenomedullin and its receptor during embryogenesis suggests autocrine or paracrine modes of action. Endocrinology 1997; 138(1): 440-51.
75. Yotsumoto S, Shimada T, Cui CY, Nakashima H, Fujiwara H, Ko MS. Expression of adrenomedullin, a hypotensive peptide, in the trophoblast giant cells at the embryo implantation site in mouse. Dev Biol. 1998; 203(2): 264-75.
76. Tsatsaris V, Tarrade A, Merviel P, et al. Calcitonin gene-related peptide (CGRP) and CGRP receptor expression at the human implantation site. J Clin Endocrinol Metab 2002; 87(9): 4383-90.
77. [] Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000; 21(2): 138-67.
78. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochro- mocytoma. Biochem Biophys Res Commun 1993; 192(2): 553-60.
79. Eto T, Kitamura K, Kato J. Biological and clinical roles of adrenomedullin in circulation control and cardiovascular diseases. Clin Exp Pharmacol Physiol 1999; 26(5-6): 371-80.
80. Jougasaki M, Burnett JC, Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci. 2000; 66(10): 855-72.
81. Caron K, Hagaman J, Nishikimi T, Kim HS, Smithies O. Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males. Proc Natl Acad Sci USA 2007; 104(9): 3420-5.
82. Kuwasako K, Cao YN, Nagoshi Y, Kitamura K, Eto T. Adrenomedullin receptors: pharmacological features and possible pathophysiological roles. Peptides 2004; 25(11): 2003-12.
83. [] Nishikimi T, Yoshihara F, Mori Y, Kangawa K, Matsuoka H. Cardioprotective effect of adrenomedullin in heart failure. Hypertens Res 2003; 26 Suppl: S121-7.
84. Yanagawa B, Nagaya N. Adrenomedullin: molecular mechanisms and its role in cardiac disease. Amino Acids. 2006.
85. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15(8): 1983-92.
86. [] Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109(23 Suppl 1): III27-32.
87. Pan CS, Zhang J, Yu F, et al. Adrenomedullin ameliorates the development of atherosclerosis in apoE-/- mice. Peptides. 2010; 31(6): 1150-8.
88. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258(5081): 468-71.
89. Jin D, Otani K, Yamahara K, Ikeda T, Nagaya N, Kangawa K. Adrenomedullin reduces expression of adhesion molecules on lymphatic endothelial cells. Regul Pept 2011; 166(1-3): 21-7.
90. Iinuma N, Sakurai T, Kamiyoshi A, et al. Adrenomedullin in sinusoidal endothelial cells play protective roles against cold injury of liver. Peptides 2010; 31(5): 865-71.
91. Kim W, Moon SO, Lee S, Sung MJ, Kim SH, Park SK. Adrenomedullin reduces VEGF-induced endothelial adhesion molecules and adhesiveness through a phosphatidylinositol 3'-kinase pathway. Arterioscler Thromb Vasc Biol 2003; 23(8): 1377-83.
92. Nossaman BD, Feng CJ, Kaye AD, et al. Pulmonary vasodilator responses to adrenomedullin are reduced by NOS inhibitors in rats but not in cats. Am J Physiol 1996; 270(5 Pt 1): L782-9.
93. Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation 1997; 95(5): 1214-21.
94. Nishimatsu H, Suzuki E, Nagata D, et al. Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta. Circ Res 2001; 89(1): 63-70.
95. Takahashi Y, de Vroomen M, Gournay V, Roman C, Rudolph AM, Heymann MA. Mechanisms of adrenomedullin-induced increase of pulmonary blood flow in fetal sheep. Pediatr Res 1999; 45(2): 276-81.
96. De Matteo R, May CN. Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide. Br J Pharmacol. 2003; 140(8): 1414-20.
97. Zhou M, Maitra SR, Wang P. Adrenomedullin and adrenomedullin binding protein-1 protect endothelium-dependent vascular relaxation in sepsis. Mol Med 2007; 13(9-10): 488-94.
98. Maki T, Ihara M, Fujita Y, et al. Angiogenic and vasoprotective effects of adrenomedullin on prevention of cognitive decline after chronic cerebral hypoperfusion in mice. Stroke 2011; 42(4): 1122-8.
99. Harada K, Yamahara K, Ohnishi S, et al. Sustained-release adrenomedullin ointment accelerates wound healing of pressure ulcers. Regul Pept. 2011; 168(1-3): 21-6.
100. Martinez A, Miller MJ, Unsworth EJ, Siegfried JM, Cuttitta F. Expression of adrenomedullin in normal human lung and in pulmonary tumors. Endocrinology 1995; 136(9): 4099-105.
101. Satoh F, Takahashi K, Murakami O, et al. Adrenomedullin in human brain, adrenal glands and tumor tissues of pheochromocytoma, ganglioneuroblastoma and neuroblastoma. J Clin Endocrinol Metab 1995; 80(5): 1750-2.
102. Miller MJ, Martinez A, Unsworth EJ, et al. Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. J Biol Chem 1996; 271(38): 23345-51.
103. Metellus P, Voutsinos-Porche B, Nanni-Metellus I, et al. Adrenomedullin expression and regulation in human glioblastoma, cultured human glioblastoma cell lines and pilocytic astrocytoma. Eur J Cancer 2011; 47(11): 1727-35.
104. Ramachandran V, Arumugam T, Hwang RF, Greenson JK, Simeone DM, Logsdon CD. Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res 2007; 67(6): 2666-75.
105. Martinez A, Vos M, Guedez L, et al. The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst 2002; 94(16): 1226-37.
106. Keleg S, Kayed H, Jiang X, et al. Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer 2007; 121(1): 21-32.
107. Zudaire E, Martinez A, Garayoa M, et al. Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol 2006; 168(1): 280-91.
108. Hata K, Takebayashi Y, Akiba S, et al. Expression of the adrenomedullin gene in epithelial ovarian cancer. Mol Hum Reprod 2000; 6(10): 867-72.
109. Cuttitta F, Pio R, Garayoa M, et al. Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. Microsc Res Tech 2002; 57(2): 110-9.
110. Ribatti D, Nico B, Spinazzi R, Vacca A, Nussdorfer GG. The role of adrenomedullin in angiogenesis. Peptides 2005; 26(9): 1670-5.
111. Garayoa M, Martinez A, Lee S, et al. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 2000; 14(6): 848-62.
112. Nikitenko LL, Smith DM, Bicknell R, Rees MC. Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB J 2003; 17(11): 1499-501.
113. Khodarev NN, Yu J, Labay E, et al. Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 2003; 116(Pt 6): 1013-22.
114. Ouafik L, Sauze S, Boudouresque F, et al. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol 2002; 160(4): 1279-92.
115. Kaafarani I, Fernandez-Sauze S, Berenguer C, et al. Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J. 2009; 23(10): 3424-35.
116. Fernandez AP, Serrano J, Tessarollo L, Cuttitta F, Martinez A. Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions. Proc Natl Acad Sci USA 2008; 105(34): 12581-6.
117. Ehlenz K, Koch B, Preuss P, Simon B, Koop I, Lang RE. High levels of circulating adrenomedullin in severe illness: correlation with C-reactive protein and evidence against the adrenal medulla as site of origin. Exp Clin Endocrinol Diabetes 1997; 105(3): 156-62.
118. Letizia C, Tamburrano G, Alo P, et al. Adrenomedullin, a new peptide, in patients with insulinoma. Eur J Endocrinol 2001; 144(5): 517-20.
119. Letizia C, De Toma G, Caliumi C, et al. Plasma adrenomedullin concentrations in patients with adrenal pheochromocytoma. Horm Metab Res 2001; 33(5): 290-4.
120. Oehler MK, Fischer DC, Orlowska-Volk M, et al. Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer. Br J Cancer 2003; 89(10): 1927-33.
121. Cotesta D, Caliumi C, Alo P, et al. High plasma levels of human chromogranin A and adrenomedullin in patients with pheochromocytoma. Tumori 2005; 91(1): 53-8.
122. Letizia C, Di Iorio R, De Toma G, et al. Circulating adrenomedullin is increased in patients with corticotropin-dependent Cushing's syndrome due to pituitary adenoma. Metabolism 2000; 49(6): 760-3.
123. Miyao Y, Nishikimi T, Goto Y, et al. Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart 1998; 79(1): 39-44.
124. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. Heart 1999; 81(5): 483-7.
125. Yoshitomi Y, Nishikimi T, Kojima S, et al. Plasma levels of adrenomedullin in patients with acute myocardial infarction. Clin Sci (Lond) 1998; 94(2): 135-9.
126. Balat A, Cekmen M, Yurekli M, et al. Adrenomedullin and nitrite levels in children with Bartter syndrome. Pediatr Nephrol 2000; 15(3-4): 266-70.
127. Evereklioglu C, Yurekli M, Er H, et al. Increased plasma adrenomedullin levels in patients with Behcet's disease. Dermatology 2000; 201(4): 312-5.
128. Ueda S, Nishio K, Minamino N, et al. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med 1999; 160(1): 132-6.
129. Yoshibayashi M, Kamiya T, Nishikimi T, Saito Y, Matsuo H, Kangawa K. Elevated plasma levels of adrenomedullin in congenital cyanotic heart disease. Clin Sci (Lond) 1999; 96(6): 543-7.
130. Tanaka M, Kitamura K, Ishizaka Y, et al. Plasma adrenomedullin in various diseases and exercise-induced change in adrenomedullin in healthy subjects. Intern Med 1995; 34(8): 728-33.
131. Cheung B, Leung R. Elevated plasma levels of human adrenomedullin in cardiovascular, respiratory, hepatic and renal disorders. Clin Sci (Lond) 1997; 92(1): 59-62.
132. Jougasaki M, Wei CM, McKinley LJ, Burnett JC, Jr. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995; 92(3): 286-9.
133. Ishimitsu T, Nishikimi T, Saito Y, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994; 94(5): 2158-61.
134. Caliumi C, Cianci R, Celi M, et al. Plasma adrenomedullin concentrations in patients with renovascular or malignant hypertension. Minerva Cardioangiol 2004; 52(4): 313-22.
135. Yamamoto K, Ikeda U, Sekiguchi H, Shimada K. Plasma levels of adrenomedullin in patients with mitral stenosis. Am Heart J 1998; 135(3): 542-9.
136. Wolk R, Svatikova A, Otto ME, Hoffmann MS, Duenwald CJ, Somers VK. Plasma adrenomedullin and obstructive sleep apnea. Am J Hypertens 2004; 17(1): 74-6.
137. Suzuki Y, Horio T, Hayashi T, et al. Plasma adrenomedullin concentration is increased in patients with peripheral arterial occlusive disease associated with vascular inflammation. Regul Pept 2004; 118(1-2): 99-104.
138. Gouya G, Sturm G, Lamina C, et al. The association of midregional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort. PLoS One. 2011; 6(3): e17803.
139. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010; 55(19): 2062-76.
140. Dhillon OS, Khan SQ, Narayan HK, et al. Prognostic value of midregional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J Am Coll Cardiol 2010; 56(2): 125-33.
141. von Haehling S, Filippatos GS, Papassotiriou J, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010; 12(5): 484-91.
142. Iacobellis G, di Gioia CR, Di Vito M, et al. Epicardial adipose tissue and intracoronary adrenomedullin levels in coronary artery disease. Horm Metab Res 2009; 41(12): 855-60.
143. Gombos T, Forhecz Z, Pozsonyi Z, et al. Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure. Inflamm Res 2009; 58(6): 298-305.
144. Nishida H, Horio T, Suzuki Y, et al. Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: comparison with C-reactive protein and adiponectin. Peptides 2008; 29(4): 599-605.
145. Teramoto S, Yamaguchi Y, Yamamoto H, et al. Effects of age and sex on plasma adrenomedullin levels in patients with obstructive sleep apnea syndrome. J Am Geriatr Soc 2007; 55(11): 1891-2.
146. Schulz R, Flototto C, Jahn A, et al. Circulating adrenomedullin in obstructive sleep apnoea. J Sleep Res 2006; 15(1): 89-95.
147. Katayama T, Nakashima H, Takagi C, Honda Y, Suzuki S, Yano K. Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock. Circ J 2005; 69(1): 83-8.
148. Katayama T, Nakashima H, Furudono S, Honda Y, Suzuki S, Yano K. Evaluation of neurohumoral activation (adrenomedullin, BNP, catecholamines, etc.) in patients with acute myocardial infarction. Intern Med 2004; 43(11): 1015-22.
149. Zhang D, Sun XF, Ma ZF, Zhu HY, Wang YD, Chen XM. Effects of high-flux hemodialysis on plasma adrenomedullin and sustained hypotension in elderly hemodialysis patients. Chin Med J (Engl) 2011; 124(6): 907-10.
150. Shinomiya K, Ohmori K, Ohyama H, et al. Association of plasma adrenomedullin with carotid atherosclerosis in chronic ischemic stroke. Peptides 2001; 22(11): 1873-80.
151. Guevara M, Gines P, Jimenez W, et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998; 114(2): 336-43.
152. Fernandez-Rodriguez CM, Prada IR, Prieto J, et al. Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. J Hepatol 1998; 29(2): 250-6.
153. Tahan V, Avsar E, Karaca C, et al. Adrenomedullin in cirrhotic and non-cirrhotic portal hypertension. World J Gastroenterol 2003; 9(10): 2325-7.
154. Mallamaci F, Zoccali C, Parlongo S, Cutrupi S, Tripepi G, Postorino M. Plasma adrenomedullin during acute changes in intravascular volume in hemodialysis patients. Kidney Int 1998; 4(5): 1697-703.
155. Tokura T, Kinoshita H, Fujimoto S, Hisanaga S, Kitamura K, Eto T. Plasma levels of mature form of adrenomedullin in patients with haemodialysis. Nephrol Dial Transplant 2001; 16(4): 783-6.
156. Cases A, Esforzado N, Lario S, et al. Increased plasma adrenomedullin levels in hemodialysis patients with sustained hypotension. Kidney Int 2000; 57(2): 664-70.
157. Yamasaki H, Nagake Y, Akagi S, Sugimoto T, Ichikawa H, Makino H. Plasma adrenomedullin levels in patients on hemodialysis. Nephron 2001; 89(1): 20-5.
158. Eto T, Washimine H, Kato J, Kitamura K, Yamamoto Y. Adrenomedullin and proadrenomedullin N-terminal 20 peptide in impaired renal function. Kidney Int Suppl 1996; 55: S148-9.
159. Ishihara T, Yokota N, Hisanaga S, et al. Increased plasma levels of mature form of adrenomedullin in patients with chronic renal failure. Clin Nephrol 1999; 52(2): 119-23.
160. Kojima H, Tsujimoto T, Uemura M, et al. Significance of increased plasma adrenomedullin concentration in patients with cirrhosis. J Hepatol 1998; 28(5): 840-6.
161. Kalman S, Buyan N, Yurekli M, Ozkaya O, Bakkaloglu S, Soylemezoglu O. Plasma and urinary adrenomedullin levels in children with acute pyelonephritis. Nephrology (Carlton) 2005; 10(5): 487-90.
162. Dieplinger B, Mueller T, Kollerits B, et al. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int 2009; 75(4): 408-14.
163. Ceyhan BB, Karakurt S, Hekim N. Plasma adrenomedullin levels in asthmatic patients. J Asthma 2001; 38(3): 221-7.
164. Kohno M, Hanehira T, Hirata K, et al. An accelerated increase of plasma adrenomedullin in acute asthma. Metabolism 1996; 45(11): 1323-5.
165. Vizza CD, Letizia C, Sciomer S, et al. Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease. Regul Pept 2005; 124(1-3): 187-93.
166. Kakishita M, Nishikimi T, Okano Y, et al. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci (Lond) 1999; 96(1): 33-9.
167. Potocki M, Breidthardt T, Reichlin T, et al. Midregional proadrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care 2009; 13(4): R122.
168. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Plasma proadrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008; 134(2): 263-72.
169. Hamada H, Saisyo K, Sekimoto T, Chosa E. Plasma adrenomedullin and proadrenomedullin N-terminal 20 peptide in patients diagnosed as having early rheumatoid arthritis. Mod Rheumatol. 2010; 20(4): 389-95.
170. Mok MY, Cheung BM, Lo Y, Leung RY, Wong WS, Lau CS. Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis. J Rheumatol 2007; 34(11): 2224-9.
171. Garcia-Unzueta MT, Martinez-Taboada VM, Amado-Senaris JA, Rodriguez-Valverde V. Plasma adrenomedullin levels in patients with polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol 2006; 24(2 Suppl 41): S6-9.
172. Balat A, Islek I, Cekmen M, et al. Adrenomedullin and total nitrite levels in children with familial Mediterranean fever. J Paediatr Child Health 2006; 42(5): 240-3.
173. Balat A, Kilinc M, Cekmen MB, et al. Adrenomedullin and total nitrite levels in children with acute rheumatic fever. Clin Biochem 2005; 38(6): 526-30.
174. Michels M, Djamiatun K, Faradz SM, Koenders MM, de Mast Q, van der Ven AJ. High plasma mid-regional pro-adrenomedullin levels in children with severe dengue virus infections. J Clin Virol 2011; 50(1): 8-12.
175. Mak A, Cheung BM, Mok CC, Leung R, Lau CS. Adrenomedullin- -a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus. Rheumatology (Oxford) 2006; 45(10): 1266-72.
176. Di Iorio R, Marinoni E, Letizia C, Villaccio B, Alberini A, Cosmi EV. Adrenomedullin production is increased in normal human pregnancy. Eur J Endocrinol 1999; 140(3): 201-6.
177. Nagata N, Kato J, Kitamura K, et al. Dissociation of adrenomedullin concentrations in plasma and cerebrospinal fluid in pregnant and non-pregnant women. Eur J Endocrinol 1998; 139(6): 611-4.
178. Poyhonen-Alho M, Viitasalo M, Nicholls MG, Lindstrom BM, Vaananen H, Kaaja R. Imbalance of the autonomic nervous system at night in women with gestational diabetes. Diabet Med 2010; 27(9): 988-94.
179. Shinozaki H, Aoki H, Kasahara Y, Kangawa K, Minegishi T. Plasma adrenomedullin levels during multiple pregnancy. Gynecol Obstet Invest 2010; 69(3): 169-73.
180. Hata T, Miyazaki K, Matsui K. Decreased circulating adrenomedullin in pre-eclampsia. Lancet. 1997; 350(9091): 1600.
181. Martinez A, Elsasser TH, Bhathena SJ, et al. Is adrenomedullin a causal agent in some cases of type 2 diabetes? Peptides 1999; 20(12): 1471-8.
182. Di Iorio R, Marinoni E, Urban G, Costantini A, Cosmi EV, Letizia C. Fetomaternal adrenomedullin levels in diabetic pregnancy. Horm Metab Res 2001; 33(8): 486-90.
183. Di Iorio R, Marinoni E, Letizia C, Gazzolo D, Lucchini C, Cosmi EV. Adrenomedullin is increased in the fetoplacental circulation in intrauterine growth restriction with abnormal umbilical artery waveforms. Am J Obstet Gynecol 2000; 182(3): 650-4.
184. Makino I, Makino Y, Yoshihara F, et al. Decreased mature adrenomedullin levels in feto-maternal tissues of pregnant women with histologic chorioamnionitis. Biochem Biophys Res Commun 2003; 301(2): 437-42.
185. Jerat S, Morrish DW, Davidge ST, Kaufman S. Effect of adrenomedullin on placental arteries in normal and preeclamptic pregnancies. Hypertension 2001; 37(2): 227-31.
186. Makino Y, Shibata K, Makino I, Ono Y, Kangawa K, Kawarabayashi T. Expression of adrenomedullin in feto-placental circulation of human normotensive pregnant women and pregnancy-induced hypertensive women. Endocrinology 1999; 140(11): 5439-42.
187. Di Iorio R, Marinoni E, Letizia C, Alo P, Villaccio B, Cosmi EV. Adrenomedullin, a new vasoactive peptide, is increased in preeclampsia. Hypertension 1998; 32(4): 758-63.
188. Lu B, Wang A, Fei Y. [Study of the plasma adrenomedullin value in pregnancy induced hypertension patients]. Zhonghua Fu Chan Ke Za Zhi. 1999; 34(1): 17-9.
189. Lauria MR, Standley CA, Sorokin Y, Yelian FD, Cotton DB. Adrenomedullin levels in normal and preeclamptic pregnancy at term. J Soc Gynecol Investig 1999; 6(6): 318-21.
190. Di Iorio R, Marinoni E, Letizia C, et al. Influence of labor on fetoplacental adrenomedullin concentrations. Am J Obstet Gynecol 2001; 185(3): 697-702.
191. El-mashad AI, Mohamed MA, Farag MA, Ahmad MK, Ismail Y. Role of uterine artery Doppler velocimetry indices and plasma adrenomedullin level in women with unexplained recurrent pregnancy loss. J Obstet Gynaecol Res 2011; 37(1): 51-7.
192. Dikensoy E, Balat O, Pence S, Balat A, Cekmen M, Yurekli M. The changes of plasma malondialdehyde, nitric oxide, and adrenomedullin levels in patients with preeclampsia. Hypertens Pregnancy 2009; 28(4): 383-9.